Report
Novartis : Pleasant surprise for Gilenya in the US… exclusivity extended
>Gilenya US, exclusivity extended – +3/5% revision of our EPS in the medium term - We have revised our model to factor in the good news from the end of last week: the commercial exclusivity for Gilenya (multiple sclerosis – the group’s biggest selling product in 2017, sales of $ 3.2bn, i.e. 6.5% of total group sales) will likely be extended thanks to the recognition of the validity of some patents (see our Equity Flash of Friday, 13 July). We are therefore no longer f...
Underlying
NOVARTIS N 2. LINIE
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Oussema Denguir
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.